Palmitoylethanolamide is a natural fatty compound the body uses to calm inflammation and settle overactive nerve signaling. Its most consistent benefit is easing ongoing nerve and joint pain, often reducing the need for other pain relievers. It is unusually well tolerated, with mild effects no more common than placebo. Long-term safety and wider healthy-aging promise remain unproven. (Full Review)

Protocol

Dose

600–1,200 mg/day

600 mg twice daily for 2–4 weeks, then 600 mg once daily for maintenance

Formulation

Micronized / ultramicronized

Reduced particle size substantially improves absorption; standard powder is less reliable

Timing

With a fat-containing meal

Split doses across the day; shifting toward evening suits those seeking its mild calming effect

Time to effect

Pain relief

2–8 weeks

Benefits build gradually with consistent use; not a fast-acting painkiller

Nerve pain

4–8 weeks

Typical window for diabetic and nerve-related pain reduction

Continued gains

Second month

Some analyses show effects continuing to grow beyond 8 weeks

Benefits

High: Chronic pain reduction

Medium: Neuropathic and diabetic nerve pain; reduced reliance on other pain medication; anti-inflammatory and neuroinflammation modulation

Low: Cognitive and neuroprotective support; intraocular pressure reduction; mood and depressive symptom support; post-viral smell recovery

Speculative: Metabolic and lipid regulation; longevity and healthy-aging support

Contraindications

Pregnancy or breastfeeding

Significant liver impairment (Child-Pugh Class C)

Known allergy to source materials or excipients

Key Interactions

Prescription analgesics and nerve-pain drugs (opioids, gabapentinoids: pregabalin, gabapentin)

OTC painkillers (NSAIDs: ibuprofen, naproxen; acetaminophen)

Anti-inflammatory supplements (luteolin, curcumin, omega-3, alpha-lipoic acid)

Sedative supplements (melatonin, magnesium, valerian)

Antidepressants (SSRIs)

Risk & Side Effects

High: Mild gastrointestinal symptoms

Medium: Absence of long-term safety data; fatigue or drowsiness

Low: Hypersensitivity or allergic reactions; additive sedation with central-acting agents

Speculative: Immune modulation with prolonged high-dose use; unknown effects in pregnancy and lactation

Monitoring

Marker	Target	Why
hs-CRP	< 1.0 mg/L	Tracks the low-grade inflammation PEA aims to reduce
ESR	< 10–15 mm/hr	Secondary, slower inflammation marker
Pain / function score (NRS or VAS)	Reduction of ≥ 2 points	Primary measure of whether PEA is working
Fasting glucose & HbA1c	Glucose 70–90 mg/dL; HbA1c < 5.4%	Context for metabolic and nerve-pain benefit
Lipid panel	Triglycerides < 100 mg/dL	Context for the speculative metabolic/lipid effects
ALT / AST	Within or near lab reference	Reassurance given liver-adjacent metabolism

Cadence: Baseline, then a review at ~6–8 weeks; every 3–6 months for continued use; inflammatory and metabolic markers rechecked every 6–12 months

Qualitative Assessment

Pain relief and function
Reduced medication use
Sleep quality
Energy and mood
Cognitive clarity

Palmitoylethanolamide for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment